McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm, M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, … ESC Scientific Document Group (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Euro Heart J 42(36):3599–3726. https://doi.org/10.1093/eurheartj/ehab368

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm, M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, … ESC Scientific Document Group (2023) 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Euro Heart J 44(37):3627–3639. https://doi.org/10.1093/eurheartj/ehad195

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, … Yancy CW (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895–e1032. https://doi.org/10.1161/CIR.0000000000001063

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105(4S):S117–S314. https://doi.org/10.1016/j.kint.2023.10.018

Article  Google Scholar 

Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, Chambless LE, Coresh J (2007) Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 18(4):1307–1315. https://doi.org/10.1681/ASN.2006101159

Article  PubMed  CAS  Google Scholar 

McAlister FA, Ezekowitz J, Tarantini L, Squire I, Komajda M, Bayes-Genis A, Gotsman I, Whalley G, Earle N, Poppe KK, Doughty RN, Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) Investigators (2012) Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail 5(3):309–314. https://doi.org/10.1161/CIRCHEARTFAILURE.111.966242

Article  PubMed  Google Scholar 

Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35(7):455–469. https://doi.org/10.1093/eurheartj/eht386

Article  PubMed  Google Scholar 

Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, Lerma EV, Mezue K, Molitch M, Mullens W, Ronco C, Tang WHW, McCullough PA, American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology (2019) Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 139(16):e840–e878. https://doi.org/10.1161/CIR.0000000000000664

Article  PubMed  Google Scholar 

Zannad F, Rossignol P (2018) Cardiorenal syndrome revisited. Circulation 138(9):929–944. https://doi.org/10.1161/CIRCULATIONAHA.117.028814

Article  PubMed  Google Scholar 

Ishida JH, Johansen KL (2016) Exclusion of patients with kidney disease from cardiovascular trials. JAMA Intern Med 176(1):124–125. https://doi.org/10.1001/jamainternmed.2015.6403

Article  PubMed  PubMed Central  Google Scholar 

Ortiz A, Navarro-González JF, Núñez J, de la Espriella R, Cobo M, Santamaría R, de Sequera P, Díez J (2021) The unmet need of evidence-based therapy for patients with advanced chronic kidney disease and heart failure: position paper from the Cardiorenal Working Groups of the Spanish Society of Nephrology and the Spanish Society of Cardiology. Clin Kidney J 15(5):865–872. https://doi.org/10.1093/ckj/sfab290

Article  PubMed  PubMed Central  Google Scholar 

Lo KB, Essa H, Wattoo A, Gulab A, Akhtar H, Sudani HA, Angelim L, Helfman B, Peterson E, Brousas S, Whybrow-Huppatz I, Yazdanyar A, Sankaranarayanan R, Rangaswami J (2023) Representation of chronic kidney disease in randomized controlled trials among patients with heart failure with reduced ejection fraction: a systematic review. Curr Probl Cardiol 48(3):101047. https://doi.org/10.1016/j.cpcardiol.2021.101047

Article  PubMed  Google Scholar 

Patel RB, Fonarow GC, Greene SJ, Zhang S, Alhanti B, DeVore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Vaduganathan M (2021) Kidney function and outcomes in patients hospitalized with heart failure. J Am Coll Cardiol 78(4):330–343. https://doi.org/10.1016/j.jacc.2021.05.002

Article  PubMed  PubMed Central  Google Scholar 

Samuels JA, Molony DA (2012) Randomized controlled trials in nephrology: state of the evidence and critiquing the evidence. Adv Chronic Kidney Dis 19(1):40–46. https://doi.org/10.1053/j.ackd.2012.01.009

Article  PubMed  Google Scholar 

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077

Article  PubMed  CAS  Google Scholar 

Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Swedberg K, Zile MR, Packer M, Desai AS, Solomon SD, McMurray JJV (2018) Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC: Heart Failure 6(6):489–498. https://doi.org/10.1016/j.jchf.2018.02.004

Article  PubMed  Google Scholar 

Abbate M, Zoja C, Remuzzi G (2006) How does proteinuria cause progressive renal damage? J Am Soc Nephrol 17(11):2974–2984. https://doi.org/10.1681/ASN.2006040377

Article  PubMed  CAS  Google Scholar 

Karalliedde J, Viberti G (2010) Proteinuria in diabetes: bystander or pathway to cardiorenal disease? J Am Soc Nephrol 21(12):2020–2027. https://doi.org/10.1681/ASN.2010030250

Article  PubMed  CAS  Google Scholar 

Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S, HOPE Study Investigators (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286(4):421–426. https://doi.org/10.1001/jama.286.4.421

Article  PubMed  CAS  Google Scholar 

Packer M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR (2018) Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol 6(7):547–554. https://doi.org/10.1016/S2213-8587(18)30100-1

Article  PubMed  CAS  Google Scholar 

Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E, PIONEER-HF Investigators (2019) Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 380(6):539–548. https://doi.org/10.1056/NEJMoa1812851

Article  PubMed  CAS  Google Scholar 

Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill N, Cockwell P, Hill M, Kalra PA, McMurray JJV, Taal M, Wheeler DC, Landray MJ, Baigent C (2018) Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease. Circulation 138(15):1505–1514. https://doi.org/10.1161/CIRCULATIONAHA.118.034818

Article  PubMed  CAS  Google Scholar 

Lee S, Oh J, Kim H, Ha J, Chun KH, Lee CJ, Park S, Lee SH, Kang SM (2020) Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. ESC Heart Fail 7(3):1125–1129. https://doi.org/10.1002/ehf2.12659

Article  PubMed  PubMed Central  Google Scholar 

Niu CY, Yang SF, Ou SM, Wu CH, Huang PH, Hung CL, Lin CC, Li SY (2022) Sacubitril/valsartan in patients with heart failure and concomitant end-stage kidney disease. J Am Heart Assoc 11(18):e026407. https://doi.org/10.1161/JAHA.122.026407

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G, Rosano GMC, Savarese G, Anker SD, Seferovic PM, Ruschitzka F, Coats AJS, Mebazaa A, McDonagh T, Sahuquillo A, Penco M, Maggioni AP, Lund LH, Heart Failure Long-Term Registry Investigators Group (2020) Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. Euro J Heart Fail 22(8):1378–1389. https://doi.org/10.1002/ejhf.1793

Article  CAS  Google Scholar 

Edner M, Benson L, Dahlström U, Lund LH (2015) Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. Eur Heart J 36(34):2318–2326. https://doi.org/10.1093/eurheartj/ehv268

Article  PubMed  CAS  Google Scholar 

Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E, Chadburn M, Cockwell P, STOP ACEi Trial Investigators (2022) Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med 387(22):2021–2032. https://doi.org/10.1056/NEJMoa2210639

Article  PubMed  CAS  Google Scholar 

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, … DAPA-HF Trial Committees and Investigators (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. New England J Med 381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303

Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Sattar N, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F, EMPEROR-Reduced Trial Committees and Investigators (2021) Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-Reduced Trial. J Am Coll Cardiol 77(11):1381–1392. https://doi.org/10.1016/j.jacc.2021.01.033

Article  PubMed  CAS